



The law firm built for business.[™]

VENTURE CAPITAL DATA

TCN Financing Roundtable January 9, 2007 Jonathan D. Gworek, Esq.



New England Trend Data*

1

	Cumulative Dividends	Participation	Weighted Average Antidilution Protection	Pay to Play	Redemption
Q2 2006	51%	65%	95%	21%	81%
Q3 2005	46%	61%	80%	26%	91%
Q3 2004	37%	63%	89%	21%	95%

* The 2004 figures above were reported by VC Experts, Inc. "Multimarket Venture Capital Survey Data: Q3 2004." The 2005 & 2006 figures above were reported by Fish & Richardson, P.C.'s "Multimarket Venture Capital Survey". In each case, the data is based on a review of publicly reported venture capital financings that took place in the New England region during the relevant periods and includes all financing rounds.



VENTURE CAPITAL DATA

Series A Rounds New England/NY/NJ

Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
1800Diapers, Inc.	BEV Capital Mentor Technology Ventures Protos LLC	\$4M	8% Non- cumulative	Νο	WA	1 of 5	Νο	Yes
Amorcyte, Inc.	Colt Investors; PA Early Stage Partners	\$4.2M	8% Non- cumulative	Yes	WA	2 of 5	No	Yes
Andrew Technologies Inc.	NJTC Venture Firm	\$400,000	8% Cumulative	No	WA	unknown	No	Yes
Applied Nanoworks, Inc.	FA Technology Ventures; FreshTracks Capital; High Peaks Venture Partners; New York State Common Retirement Fund; Village Ventures	\$2M	8% Cumulative	Yes	FR for the period of time up to the 2nd annv. of the issuance of the Series A; WA thereafter	2 of 5	Νο	Yes

"WA" means weighted average; "FR" means full ratchet.

* The information reported in the above table was obtained from publicly available charter documents and other publicly available resources and has not been confirmed by the relevant companies. Approximately 55 charters covering Q1, Q2 and Q3 of 2006.



VENTURE CAPITAL DATA

Series A Rounds New England/NY/NJ

							Pay	
Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	to Play	Redemption
Arcadian Networks, Inc.	Clal Industries and Investments; Gilo Ventures; Goldman Sachs & Co,; Twinwood Capital Management	\$60M	Νο	Yes	WA	2 of 7	No	Νο
Arradiance, Inc.	Highland Capital Partners; Miramar Venture Partners; US Venture Partners	\$750,000	8% Non- cumulative	Yes	WA	3 of unknown total	Νο	No
Artisan Therapeutics, Inc.	Bio*One Capital, JAFCO American Ventures, New Leaf Venture Partners, NGN Capital, Quintiles Transnational	\$39M	6% Cumulative	Yes	WA	5 of 8	No	Yes
Bus Radio, Inc.	Sigma Partners	\$2M	Νο	No	WA	2 of unknown total	No	Yes
Cirrata, Inc.	Connecticut Innovations; L&L Capital Partners	\$1.5M	6% Cumulative	No	WA	unknown	No	Yes

© 2007 Morse Barnes-Brown & Pendleton, P.C.



Series A Rounds New England/NY/NJ

Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
CMWare, Inc.	Updata Partners	[\$6M] *	8% Cumulative	Yes	WA	2 of 5	No	Yes
Dataupia Corporation	Polaris Venture Partners; Valhalla Partners	\$15M	Νο	Νο	WA	2 of unknown total	No	Yes
Decimmune Therapeutics, Inc.	Amgen Ventures; Healthcare Ventures	\$2M	8% Cumulative	Yes	FR	3 of unknown total	No	Yes
Endovalve, Inc.	Battelle Ventures	\$2.5M	8% Cumulative	Yes	WA	Unknown	No	Νο
Eons, Inc.	General Catalyst Partners; Monster Worldwide; Sequoia Capital	\$10M	5% Cumulative	Νο	WA	2 of unknown total	No	Yes
G8Wave, Inc.	ITU Ventures	\$7.5M	8% Non- Cumulative	Yes	WA	unknown	No	Yes

* Not reported. Speculative number determined by multiplying Series A price per share by total authorized Series A shares.

© 2007 Morse Barnes-Brown & Pendleton, P.C.



Series A Rounds

		/	New England/NY/NJ					
Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
Global Resource Options, Inc.	Allco Financial Group, Calvert Group, SJF Ventures II, LP	\$2.25M	8% Cumulative		WA	2 of 5	Νο	Yes
Histogenics Corporation	Boston Millennia Partners, Foundation Medical Partners, Howmedica Osteonics	\$13.1M	8% Cumulative	No	WA	4 of unknown total	Νο	Yes
iCardiac Technologies, Inc.	Trillium Group	\$2M	3% Cumulative	Yes	WA	7 of unknown total	No	Yes
IGA Worldwide, Inc.	DN Capital; Easton Capital Investment Group; Intel Capital; Morganthaler	\$17 M	Νο	Yes	FR up to 1st anniversary; WA thereafter	3 of unknown total	No	No
Innocentive, Inc.	Lilly Ventures; Omidyar Network; Spencer Trask Ventures	\$9M	Νο	No	WA	Unknown	No	No



Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
Innovation Engineering, Inc.	NJTC Venture Fund	\$1 M	8% Cumulative	Yes	WA	2 of 5	No	Yes
IntegriChain, Inc.	NJTC Venture Fund	\$2M	8% Cumulative	Yes	WA	2 of unknown total	No	Yes
KickApps Corporation	Prism Venture Partners; Spark Capital	\$6M	8% Non- cumulative	No	WA	2 of unknown total	No	Yes
Logical Images, Inc.	Ticonderoga Capital	\$2.7M	8% Cumulative	Νο	WA	1 of unknown total	No	Yes
Longwatch, Inc.	Inflection Point Ventures; Venture Capital Fund of NE	\$4.1M	8% Cumulative	Yes	WA	3 of unknown total	Νο	No
Lux Biosciences, Inc.	HBM Partners; International Biotechnology Trust; Novo; Prospect Venture Partners; SV Life Sciences	\$49M	8% Non- cumulative	Yes	WA	4 of unknown total	Yes	Νο



Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
M5 Networks, Inc.	Edison Venture Fund; Greycroft; Milestone Venture Partners	\$7.75M	Νο	Νο	WA	Unknown	No	Yes
MedVentive Inc.	HLM Venture Partners, Long River Ventures, Village Ventures	\$4M	6% Cumulative	Νο	WA	2 of 5	No	Yes
Motionbox, Inc.	Canaan Partners, ITOCHU Corporation, SAS Investors	4.2M	8% Non- cumulative	Νο	WA	3 of 7	No	Yes
MyoScience, Inc.	Accuitive Medical Ventures, De Novo Ventures	\$3.2M	8% Non- cumulative	Νο	WA	2 of unknown total	No	Νο
Noble Device Technologies Corporation	Matrix Partners, North Bridge Venture Partners	\$8M	Νο	Yes	WA	2 of 5	No	Yes



Series A Rounds New England/NY/NJ

Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
nTAG Interactive Corporation	Pilot House Ventures Group, Sevin Rosen Funds	\$12.7 M	8% Non- cumulative	Yes	WA	2 of unknown total	Yes	No
On Deck Capital	Contour Venture Partners, First Round Capital, Village Ventures	\$2M	3% Cumulative	Yes	WA	3	No	Yes
Orthocon, Inc.	BB Biotech Ventures, Canaan Partners, Rockport Venture Partners	\$10M	8% Cumulative	Yes	WA	2 of unknown total	No	Yes
Panther Express	Greylock	\$6M	No	Yes	WA	1 of 5	No	No
Phreesia, Inc.	HLM Venture Partners	\$2.1M	8% Cumulative	No	WA	3 of unknown total	No	Yes



Series A Rounds New England/NY/NJ

Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
Pump Audio, Inc.	Greycroft, High Peaks Venture Partners, Village Ventures	[\$1.86 M]*	8% Cumulative	Yes	WA	2 of 6	Νο	Yes
Reflexis Systems, Inc.	Pequot Ventures	\$10M	7.87% Non- cumulative	Νο	WA	1 of unknown total	No	Yes
Sermo, Inc.	Longworth Venture Partners	\$3M	6% Cumulative	Yes	WA	1 of unknown total	Νο	Yes
Synovex Corporation	HealthCare Ventures; MedImmune	\$1.6M	8% Cumulative	Yes	WA	4 of 7	Νο	Yes
TripConnect, Inc.	Masthead	NA	6% Cumulative	Yes	WA	2 of 5	No	Yes
Veracode, Inc.	Atlas Ventures Polaris Venture Partners	\$7M	No	Yes	WA	2 of 3	Yes	Yes

* Not reported. Speculative number determined by multiplying Series A price per share by total authorized Series A shares.



Series A Rounds New England/NY/NJ

Name	Investor	Amount Raised	Dividends	Participation	Antidilution Protection	Preferred Board Seats	Pay to Play	Redemption
Vivadee, Inc.	Trident Capital	[\$6.3M]*	8% Non- cumulative	Yes	WA	2 of 5	No	Yes
Wavemark, Inc.	Loeb Partners Corp. and SRK Management Co.	\$9.5M	8% Cumulative	Νο	FR	2 of 5	No	Νο
Xceedium	ArrowPath Venture Capital; Nationwide Mutual Capital	5M	Νο	Yes	WA	2 of unknown total	No	Yes
Zingku, Inc.	Flagship Ventures	\$1M	8% Cumulative	Νο	WA	1 of unknown total	No	Νο

* Not reported. Speculative number determined by multiplying Series A price per share by total authorized Series A shares.



2006 Series A Rounds New England/NY/NJ

Cumulative Dividends	Participation	Weighted Average Antidilution Protection	Pay to Play	Redemption
54%	60%	92%	6%	76%

* The information reported in the above table was obtained from publicly available charter documents. Approximately 55 charters covering Q1, Q2 and Q3 of 2006.



Trend Data

	Cumulative Dividends	Participation	Weighted Average Antidilution Protection	Pay to Play	Redemption
2006 Series A Rounds*	54%	60%	92%	6%	76%
All Rounds Q2 2006**	51%	65%	95%	21%	81%
All Rounds Q3 2005**	46%	61%	80%	26%	91%
All Rounds Q3 2004**	37%	63%	89%	21%	95%

* The information reported in the above table was obtained from publicly available charter documents. Approximately 55 charters covering Q1, Q2 and Q3 of 2006.

** The 2004 figures above were reported by VC Experts, Inc. "Multimarket Venture Capital Survey Data: Q3 2004." The 2005 & 2006 figures above were reported by Fish & Richardson, P.C.'s "Multimarket Venture Capital Survey". In each case, the data is based on a review of publicly reported venture capital financings that took place in the New England region during the relevant periods and includes all financing rounds.



Name	Series A Price Per Share	Total Common Authorized	Total Preferred Authorized	Option Pool After Sale of Series A
1800Diapers, Inc.	\$1.550	10,000,000	2,750,000	
Amorcyte, Inc.	\$798.65	30,000	6,150	
Andrew Technologies Inc.	\$1.00	1,500,000	600,000	
Applied Nanoworks, Inc.	\$1.00	4,700,000	2,000,000	480,522
Arcadian Networks, Inc.	\$1.00	198,148,556	75,000,000	15,663,918
Arradiance, Inc.	\$0.40	12,000,000	5,626,000	2,000,000
Artisan Therapeutics, Inc.	\$2.00	37,300,000	22,000,000	4,161,659
Bus Radio, Inc.	\$1.00	10,100,000	4,200,200	1,365,000
Cirrata, Inc.	\$271.20	25,000	5,716	



Name	Series A Price Per Share	Total Common Authorized	Total Preferred Authorized	Option Pool After Sale of Series A
CMWare, Inc.	\$0.35	35,000,000	16,920,473	3,410,982
Dataupia Corporation	\$0.80	30,000,000	16,218,750	5,090,000
Decimmune Therapeutics, Inc.	\$0.60	7,700,000	3,500,000	567,000
Endovalve, Inc.	\$0.314	11,452,002	7,974,482	2,477,520
Eons, Inc.	\$1.14783	26,304,990	8,722,984	
G8Wave, Inc.	\$1.05	25,000,000	7,172,500	
Global Resource Options, Inc.	\$1.00	20,000,000	5,000,000	
Histogenics Corporation	\$1.33	70,000,000	51,403,368	
iCardiac Technologies, Inc.	\$1.293	10,00,000	3,093,581	1,614,756



Name	Series A Price Per Share	Total Common Authorized	Total Preferred Authorized	Option Pool After Sale of Series A
IGA Worldwide, Inc.	\$1.00	31,510,013	16,836,845	3,000,00
Innocentive, Inc.	\$1.00	45,000,000	15,000,000	
Innovation Engineering, Inc.	\$51.965	2,000,000	200,000	
IntegriChain, Inc.	\$0.87437	7,712,642	2,287,358	821,309
KickApps Corporation	\$0.60	21,666,667	11,666,667	
Logical Images, Inc.	\$1.57	20,000,000	1,719,745	
Longwatch, Inc.	\$4.00	4,000,000	3,500,000	175,000
Lux Biosciences, Inc.	\$1.00	63,998,168	50,000,000	
M5 Networks, Inc.	\$6.506	10,000,000	5,000,000	1,048,936
MedVentive Inc.	\$1.00	4,000,000	4,000,000	1,747,500



Name	Series A Price Per Share	Total Common Authorized	Total Preferred Authorized	Option Pool After Sale of Series A
Motionbox, Inc.	\$0.4341	41,750,000	11,750,000	4,000,000
MyoScience, Inc.	\$0.80	10,000,000	4k200k000	
Noble Device Technologies Corporation	\$1.00	15,210,000	8,210,000	3,375,000
nTAG Interactive Corporation	\$1.00	21,000,000	15,250,000	
On Deck Capital	\$0.72	6,173,484	2,743,484	432,500
Orthocon, Inc.	\$0.891	25,456,818	11,228,409	1,253,841
Panther Express	\$1.00	65,000,000	6,200,000	3,300,329
Phreesia, Inc.	\$1.00	10,000,000	2,500,000	
Pump Audio, Inc.	\$4.67	2,000,000	400,000	183,000
Reflexis Systems, Inc.	\$1.27	26,900,000	8,274,016	



Series A Price Per Share	Total Common Authorized	Total Preferred Authorized	Option Pool After Sale of Series A
\$1.00	5,025,000	2,026,250	1,025,000
\$1.00	13,400,000	6,600,000	
\$0.50	10,000,000	2,048,000	744,681
\$1.00	13,500,000	8,047,778	3,022,222
\$1.00	12,900,000	6,300,000	2,400,000
\$0.94	14,500,000	10,377,789	1,968,650
\$1.00	9,500,000	6,350,000	2,562,734
\$1.00	5,000,000	1,000,000	
	\$1.00 \$1.00 \$0.50 \$1.00 \$1.00 \$0.94 \$1.00	Series A Price Per Share Authorized \$1.00 5,025,000 \$1.00 13,400,000 \$0.50 10,000,000 \$0.50 10,000,000 \$1.00 13,500,000 \$1.00 12,900,000 \$0.94 14,500,000 \$1.00 9,500,000	Series A Price Per Share Authorized Authorized \$1.00 5,025,000 2,026,250 \$1.00 13,400,000 6,600,000 \$0.50 10,000,000 2,048,000 \$1.00 13,500,000 8,047,778 \$1.00 12,900,000 6,300,000 \$1.00 14,500,000 6,350,000



NEWCO, INC.

Summary of Terms for Series A Convertible Preferred Stock Investment

Type of Security:	Series A Convertible Preferred Stock of the Company ("Series A Preferred")				
Pre-Money Valuation:	\$5,500,000				
Number of Shares/Purchase Price:	7,000,000 shares of Series A Preferred at \$1.00 per share (the "Purchase Price").				
Aggregate Purchase Price:	The aggregate purchase price will be \$7.0 million (representing 50% of the Company on a fully-diluted basis post-financing including an available option pool of 14%).				
Post-Financing Ownership: (Fully Diluted Basis)	<u>Class</u> Founders Stock Option Pool Series A Preferred	<u>Shares Owned</u> 13,586,670 shares 3,999,336 shares 8,722,984 shares	<u>Percentage</u> 52% 15% 33%		
Rights, Preferences, Privileges and Restrictions of Series A Preferred:	 Series A Preferred 8,722,994 shares 33% (1) <u>Dividend Provisions.</u> 5% cumulative dividend. (2) <u>Liquidation Preference</u>. Non-participating. (3) <u>Optional Conversion</u>. Convertible any time at the option of the holders of Series A. (4) <u>Automatic Conversion</u>. IPO of \$25M or more at a price per share of 5X original purchase price <i>or</i> the consent of the holders of 2/3 of Series A. (5) <u>Antidilution Provisions</u>. Broad based weighted average. (6) <u>Redemption Provisions</u>. 5 years out by consent of the holders of 2/3 of Series A. (7) <u>Voting Rights</u>. Series A and common stock vote together on an asconverted basis except for protective provisions. (8) <u>Board of Directors</u>. Series A elect 2 of 5. (9) <u>Protective Provisions</u>. Blocking rights over fundamental transactions so long as 15% of the Series A originally issued remains outstanding. 				



NEWCO, INC.

Option Pool Sensitivity Analysis

<u>Actual at</u> <u>\$7M Pre-\$7M In-14% Pool</u>

Hypothetical at \$14M Pre-\$7M In-31% Pool

<u>Class</u>	<u>Shares</u> Owned	Percentage	<u>Class</u>	<u>Shares</u> Owned	Percentage
Founders	5,000,000	36%	Founders	7,636,364	36%
Option Pool	2,000,000	14%	Option Pool	6,575,757	31%
Series A	7,000,000	50%	Series A	7,000,000	33%